Premium
Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia
Author(s) -
Fervaha G.,
Foussias G.,
Agid O.,
Remington G.
Publication year - 2014
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/acps.12289
Subject(s) - neurocognitive , amotivation , schizophrenia (object oriented programming) , psychology , psychopathology , longitudinal study , clinical psychology , multivariate analysis , cognition , psychiatry , medicine , intrinsic motivation , social psychology , pathology
Objective Functional impairment is characteristic of most individuals with schizophrenia; however, the key variables that undermine community functioning are not well understood. This study evaluated the association between selected clinical variables and one‐year longitudinal functional outcomes in patients with schizophrenia. Method The sample included 754 patients with schizophrenia who completed both baseline and one‐year follow‐up visits in the CATIE study. Patients were evaluated with a comprehensive battery of assessments capturing symptom severity and cognitive performance among other variables. The primary outcome variable was functional status one‐year postbaseline measured using the Heinrichs‐Carpenter Quality of Life Scale. Results Factor analysis of negative symptom items revealed two factors reflecting diminished expression and amotivation. Multivariate regression modeling revealed several significant independent predictors of longitudinal functioning scores. The strongest predictors were baseline amotivation and neurocognition. Both amotivation and neurocognition also had independent predictive value for each of the domains of functioning assessed (e.g., vocational). Conclusion Both motivational and neurocognitive deficits independently contribute to longitudinal functional outcomes assessed 1 year later among patients with schizophrenia. Both of these domains of psychopathology impede functional recovery; hence, it follows that treatments ameliorating each of these symptoms should promote community functioning among individuals with schizophrenia.